Patrick Roberts Is Betting the Cell Cycle Has Another Door

After helping a small North Carolina biotech move a cell-cycle drug from discovery toward patients, Patrick Roberts reunited with longtime colleagues to pursue a harder target: CDK2. The wager behind Incyclix Bio is that precision, patience and the right biomarkers can reopen a route that resistant cancers have learned to use.